ARUP Experts To Share Laboratory Medicine Research at AAIC and ADLM Conferences

Medical directors, fellows, scientists, and lab management consultants from ARUP Laboratories will showcase their latest research and advancements in diagnostics for Alzheimer’s disease (AD) and laboratory medicine at two upcoming conferences.

The Association for Diagnostics and Laboratory Medicine (ADLM) conference, held July 27–31 in Chicago, spotlights vital research in laboratory medicine and important updates in the field.

The Alzheimer's Association International Conference (AAIC) will be held July 27–31 in Toronto, Canada. It features dementia research and allows experts to share breakthroughs and best practices.

Not to be missed at ADLM is the session “Expand Your Reach: Unlocking Hospital Laboratory Potential Through Outreach,” during which members of ARUP’s Healthcare Advisory Services team will present on lab management topics:

• David Shiembob, MBA, C(ASCP)^CM, manager of ARUP Healthcare Advisory Services, will cover how to best measure the financial impact of adding new test volumes into an existing laboratory.
• Christopher Rabideau, MBA, MLS(ASCP)^CM, senior healthcare consultant for ARUP Healthcare Advisory Services, will explore the operational considerations around successfully integrating outside testing into a hospital laboratory.

During the session, Jayne Ellenwood, MHA, MLS(ASCP), quality manager at Bryan Medical Center Laboratory, will also share her hospital laboratory’s journey in building a successful outreach program.

One key advancement that will be shared at both conferences is ARUP’s new Phospho-Tau 217, Plasma (3019017) assay, used to evaluate for AD and other causes of cognitive impairment in adults 60 years and older who present with cognitive decline. Phosphorylated tau 217 (pTau 217) is a blood-based biomarker for AD and current research supports it as a highly accurate and specific marker for the detection of amyloid pathology. Because the biomarker can be detected in blood, this test is minimally invasive, more broadly accessible, and enables earlier detection of AD when compared with traditional cerebrospinal fluid (CSF)-based biomarkers.  

More information on the development and validation of this assay will be shared at AAIC by Heather Nelson, PhD, DABCC, ARUP medical director of Clinical Chemistry and Mass Spectrometry. At ADLM, Sonia La’ulu, MBA, C(ASCP), ARUP scientific manager in Research and Development; Alan Erickson, PhD, ARUP scientist in Research and Development, Special Chemistry; and other ARUP experts will present on laboratory medicine research. Review the complete list of ARUP’s presentations and posters for each conference below.

Alzheimer's Association International Conference
Toronto, Canada, July 27–31, 2025

Posters

Analytical Validation of Plasma P-tau217 on the SP-X Platform

Nelson HA, Erickson JA, La’ulu SL, Cunningham SD, Doyle K

Clinical Validation of a Plasma P-tau217 Immunoassay and Evaluation of the Impact of Kidney Function

Nelson HA, La’ulu SL, Erickson JA, Cunningham SD, Doyle K

Association for Diagnostics and Laboratory Medicine
Chicago, July 27–31, 2025

Posters

Distinguished Abstract Award: Performance Validation of a Plasma-Based Immunoassay for P-tau217

Erickson JA, La’ulu SL, Cunningham SD, Doyle K, Nelson HA

Clinical Validation of a Plasma-Based P-tau217 Immunoassay

La’ulu SL, Erickson JA, Cunningham SD, Nelson HA, Doyle K

Performance Evaluation of an Automated Test System for Determining the Soluble fms-Like Tyrosine Kinase/Placental Growth Factor Ratio

Erickson JA, La’ulu SL, Nelson HA, Doyle K

Evaluation of Activated Aspartate Aminotransferase (A-AST) Assay Using the Abbott Alinity c and Architect c4000

Villanueva MG, Law RN, La’ulu SL, Wyness SP, Pandya V

Evaluation of the Relationship Between H-Index- and Hemoglobin-Normalized Glucose-6-Phosphate Dehydrogenase and Pyruvate Kinase Activities

Udechukwu MC, Doyle K

Validation of the Diagnostics Biochem Canada Vasoactive Intestinal Peptide (VIP) ELISA

Hunsaker JJH, Villanueva MG, Billones R, La’ulu SL, Moss TJ, Merrell M, Straseski JA

Validation of a Copeptin Immunoassay as a Surrogate for Vasopressin Testing

Lu J, La’ulu SL, Doyle K

Evaluation of an In-House Cholinesterase Assay for Serum, Plasma, and Whole Blood

Lu J, La’ulu SL, Doyle K

On Importance of Monitoring UDCA Treatment in Intrahepatic Cholestasis of Pregnancy

Schramm K, Ray JA, Kushnir MM, Vachali P, Yuzyuk T

Evaluation of Immunalysis Carisoprodol Metabolite / Meprobamate Urine Homogeneous Enzyme Immunoassay (HEIA) on the AU5800

Jackson AN, La’ulu SL, Rudolf JW, Johnson-Davis KL, Boyd JM

Validation of Alzheimer’s Disease Markers in CSF

Allison TA, La’ulu SL, Hunsaker JJH, Doyle K, Nelson HA

Presentations

Evaluation of Stanbio Laboratory β-Hydroxybutyrate Using the Abbott Alinity c Analyzer

Law R, Wyness S, La’ulu SL, Pandya V

Practical Considerations in Evaluating and Implementing Artificial Intelligence Solutions for Today’s Clinical Laboratorian

Mathias P, Obstfeld A, Spies N, Foy B, Stoffel M

Advancing Patient Safety Through Global Laboratory Quality Indicators: Insights From the IFCC Model

De Guire V, Genzen J, Li JS

Expand Your Reach: Unlocking Hospital Laboratory Potential Through Outreach

Shiembob D, Rabideau C, Ellenwood J

Stick to the Norm: Performing Reference Interval Verification Studies

La’ulu SL

Practical Considerations in Evaluating Screening and Confirmation Urine Drug Tests: Fentanyl as an Example

Rongrong H, Boyd JM, Gherasim C

Federal Oversight of LDTs: Where We Are and Where We’re Going

Genzen J, Lockwood C

Role of Component Resolved Resting in Food Allergies: From Peanuts to Tick-Borne Red Meat Allergies

Saadalla A, Slev P

Analytical Approaches to Preanalytical Errors

Lin Y, Spies N, Merrill A

Thinking Beyond Creatinine: Next-Generation Biomarkers for Early Prediction and Diagnosis of Acute Kidney Injury

Pandya V

Data Science Symposium: IV Fluid Contamination in CBCs Motivates Unnecessary RBC Transfusions
Spies N

Alice To, alice.to@aruplab.com